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ABSTRACT
Background: Sorafenib is the current standard of care for patients with advanced 
or metastatic hepatocellular carcinoma. Currently no universally agreed model exists 
correlating the Neutrophil Lymphocyte ratio (NLR) and non-secretion of AFP with the 
survival of HCC patients treated with sorafenib.
Patients and Methods: We retrospectively analysed patient records with a 
confirmed diagnosis of HCC treated with sorafenib between April 2009 and March 
2014. Survival analysis was performed using the Kaplan–Meier method and Cox 
regression.
Results: Patients separated into groups based on NLR (≤3 or >3), or AFP 
secretion profile (<7 ng/ml or ≥7 ng/ml) derived diverging Kaplan–Meier curves for 
overall survival (OS). The median OS in those with NLR ≤3.0 was 9.0 months (95% 
CI: 7.7–11.1 months) and in those with NLR >3.0 it was 6.0 months (95% CI: 4.9–8.2 
months) [HR 1.32 (95% CI: 0.96–1.80)]. The median overall survival post sorafenib 
was higher in the “non-secretor” AFP group. OS for AFP <7 ng/ml was 10.0 months 
(95% CI: 7.7–19.3 months) compared to AFP ≥7ng/ml: 6.6 months (95% CI: 5.3–8.4 
months) [HR 1.64 (95% CI: 1.15–2.33)]. 
Conclusion: NLR and AFP non - secretion at diagnosis are potential significant 
prognosticators for overall survival from initiation of sorafenib.
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a highly 
aggressive malignancy representing the sixth most 
common cancer and the third leading global cause of 
cancer related deaths [1, 2]. In the western world the 
incidence of HCC is still rising [1]. Unfortunately, the 
majority of patients present at an advanced, non-curative 
stage. 
The Barcelona Clinic Liver Cancer (BCLC) 
algorithm is an accepted and validated staging system, 
providing a framework for the management of HCC [3]. 
Patients with good liver synthetic function and early stage 
tumour (BCLC 0, A) are eligible for curative treatment 
options whereas patients with poor liver function and 
performance status (BCLC D) are advised best supportive 
care. Patients within BCLC B and C category are 
eligible for palliative treatment options (loco-regional 
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or systemic). Despite significant improvements in loco-
regional and targeted treatment, the long term outcome for 
patients with advanced HCC remains poor [2].
The ‘SHARP’ and ‘Asia-Pacific’ studies have 
established sorafenib as the current standard of care 
for patients with advanced HCC in the first line setting 
[4, 5]. Sorafenib is an orally active multikinase inhibitor of 
Raf, Platelet-derived Growth Factor (PDGF) and Vascular 
Endothelial Growth Factor (VEGF) receptors [6]. A body 
of evidence exists for the wide heterogeneity of response 
to sorafenib, but robust prognosticators in this setting are 
lacking [7–10].
There is increasing evidence that cancer-related 
inflammation plays an important role in cancer 
development and progression, through upregulation 
of cytokines and inflammatory mediators [11]. This is 
especially the case in HCC which usually arises on a 
background of chronic hepatitis and cirrhosis. Indeed 
genomic studies of the adjacent non-neoplastic tissue in 
HCC following surgical resection have identified a pro-
inflammatory gene signature that predicts late recurrence 
and poor survival [12]. The neutrophil-to-lymphocyte 
ratio (NLR) is one measure of the systemic inflammatory 
response with the advantage that it can be readily assessed 
through a peripheral blood test. An elevated NLR has 
been associated with a poorer overall survival in many 
solid tumours [13]. Three recent systematic reviews (the 
largest involving 20475 patients) have also demonstrated 
that NLR is a major prognostic factor in HCC; a high 
baseline NLR was associated with adverse disease-free 
and/or overall survival in patients with HCC [14–16]. 
Furthermore, subgroup analyses showed that baseline 
NLR was prognostic of overall survival for all treatment 
options in HCC (with the exception of radiofrequency 
ablation), although the sorafenib group was made up of 
only two small retrospective studies with 102 and 68 
patients respectively [16–18]. 
Alpha-fetoprotein (AFP) levels have also been 
investigated as a marker to predict the response of 
HCC patients after loco-regional treatment or systemic 
chemotherapy. AFP is a serum glycoprotein that was 
first identified nearly 50 years ago [19]. It is synthesised 
in high levels by the foetal yolk sac and foetal liver 
but its expression is then repressed shortly after birth. 
Reappearance of AFP in the circulation in adults is 
associated with chronic hepatitis and liver cirrhosis as 
well as malignancies such as HCC and gastrointestinal 
cancers of endodermal origin [20]. AFP is secreted into 
the blood of approximately 70% of all patients with 
HCC and higher levels have been found to be associated 
with a worse prognosis [21–25]. Consequently, AFP has 
been incorporated into many of the available scoring and 
staging systems for HCC. However 30–50% of patients 
with unresectable HCC do not have elevated AFP levels, 
representing a significant proportion of this group [26, 27]. 
Patients with low AFP are known to have better prognosis 
but apart from this, there is a paucity of data regarding 
prognostic biomarkers in this subgroup of patients. 
In this large cohort study of 231 patients at an 
academic cancer centre in the UK, we aimed to correlate 
the response to sorafenib with NLR and non-secretion of 
AFP and assess their validity as prognostic biomarkers for 
HCC.
RESULTS 
Baseline characteristics
A total of 231 patients were included in the 
preliminary notes review. 17 were excluded at first review 
for unconfirmed diagnosis of HCC or not receiving 
sorafenib. The remaining 214 selected patients consisted 
of 172 (79%) males and 45 (21%) females. (Table 1A).
The patients were stratified into two groups 
according to NLR: Low NLR group <3 (n = 104) and high 
NLR group >3 (n = 110). The two groups were generally 
well balanced for sex, age, Child-Pugh class (CP), portal 
vein invasion and previous treatments (in categories with 
more than a few patients), with the low NLR group having 
a slightly lower age profile. The low NLR group also had 
a lower AFP profile with more “non-secretors” (AFP <7 
ng/ml) and fewer patients with high AFP (>400 ng/ml) 
than the high NLR group. There were more patients with 
hepatitis (B and C) and alcoholic liver disease (ALD) in 
the low NLR group.
We also stratified the patients by AFP secretion 
status. Non-secretors were defined as having an AFP of <7 
ng/ml (n = 62) and secretors as having an AFP >7 ng/ml 
(n= 152). We further analysed the baseline characteristics 
of these AFP secretor groups (Table 1B). Both groups were 
generally well balanced for age, CP class, aetiological 
factors for HCC and previous treatments, with the non-
secretor group having a slightly lower age profile. There 
was a marked imbalance between the two groups for sex 
with a much higher proportion of men in the non-secretor 
group. There were also more patients with portal vein 
invasion in the secretor group.
Overall survival 
NLR
The median overall survival in those with NLR 
≤3.0 was 9.0 months (95% CI: 7.7–11.1 months) and in 
those with NLR >3.0 it was 6.0 months (95% CI: 4.9–8.2 
months). (Figure 1). The hazard ratio of NLR > 3 to NLR 
≤3 indicate that higher NLR is associated with shorter 
survival times (HR1.45 (95% CI: 1.07, 1.95)). When 
adjusted for CP class, portal vein invasion and AFP the 
trend was still apparent (HR1.32 (95% CI: 0.96, 1.80)). 
This statistical significance was lost when the NLR ratio 
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was increased to 4 or 5 but HR trend was maintained. Loss 
of statistical significance in our cohort may be related to 
small sample size (Table 2). 
A log-rank test comparing NLR < 3 with NLR ≥ 
3 found a statistically significant difference between the 
survival outcomes for the two groups: (p = 0.015). A 
log-rank test stratified by CP class, portal vein invasion 
and AFP level (<7 ng/ml) was marginally significant (p 
= 0.055). We used backwards elimination method for 
significant variables.
AFP
The median overall survival post sorafenib was 
higher in the “non-secretor” AFP groups. OS for AFP 
<7 ng/ml was 10.0 months (95% CI: 7.7–19.3 months) 
compared to AFP ≥ 7 ng/ml: 6.6 months (95% CI: 5.3–8.4 
months). (Figure 2). The non-secretors of AFP showed an 
unadjusted HR of 1.87 (95% CI 1.3–2.6) and an adjusted 
HR of 1.64 (95% CI: 1.2–2.3) for CP class, portal vein 
invasion, previous treatment.
A log-rank test comparing AFP < 7 ng/ml with AFP = 
>7 ng/ml found a highly statistically significant difference 
between the survival outcomes for the two groups: (p = 
0.0003). A log-rank test stratified by CP class, portal vein 
invasion and previous localised treatments (RFA/TACE) 
was also statistically significant (p = 0.0080). 
DISCUSSION
Sorafenib was established as the first treatment to 
improve overall survival in patients with advanced HCC 
in 2008 [4, 5], yet to date, there remains no validated 
predictive or prognostic biomarker for its use. We show 
that NLR and non-secretion of AFP have potential to be 
prognostic biomarkers in this setting with the additional 
advantages of being readily available and inexpensive.
In this large single-centre cohort of consecutive 
patients treated with sorafenib, we observed that 
patients with an elevated pre-treatment NLR (>3) have a 
significantly worse overall survival following treatment 
with sorafenib compared with patients with a NLR ≤3. Our 
results are consistent with the emerging data in this area 
and adds to the evidence base; since we embarked on this 
study there are now three small retrospective studies and 
one large observational study that have all demonstrated 
Table 1A: Baseline Characteristics NLR groups
NLR ≤ 3 (n = 104) NLR > 3 (n = 110) All patients (n = 214)
Sex Male 82 (79%) 88 (80%) 170 (79%)
Female 22 (21%) 22 (20%) 44 (21%)
Age (n = 207) Median (IQR) 65 (60, 73) 67 (61, 74) 66 (60, 74)
Range 14 – 86 15 – 82 14 – 86
≤ 66 56 (55%) 49 (46%) 105 (51%)
>66 45 (45%) 57 (54%) 102 (49%)
Child-Pugh A 69 (66%) 71 (65%) 140 (65%)
B 33 (32%) 37 (34%) 70 (33%)
C 2 (2%) 2 (2%) 4 (2%)
AFP <7 ng/ml 40 (38%) 22 (20%) 62 (29%)
≥7 ng/ml < 400 ng/mL 40 (38%) 42 (38%) 82 (38%)
≥ 400 ng/ml 24 (23%) 46 (42%) 70 (33%)
Portal vein invasion Yes 68 (65%) 70 (64%) 138 (64%)
No 36 (35%) 40 (36%) 76 (36%)
Aetiology ALD 18 (17%) 12 (11%) 30 (14%)
Hepatitis B 11 (11%) 6 (5%) 17 (8%)
Hepatitis C 17 (16%) 7 (6%) 24 (11%)
NASH 8 (8%) 10 (9%) 18 (8%)
Combination 2 (2%) 10 (9%) 12 (6%)
Unknown/other 48 (46%) 65 (59%) 113 (53%)
Previous treatment TACE 24 (23%) 32 (29%) 56 (26%)
RFA 7 (7%) 1 (1%) 8 (4%)
TACE & RFA 7 (7%) 1 (1%) 8 (4%)
None 66 (63%) 76 (69%) 142 (66%)
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Table 1B: Baseline Characteristics AFP secretors groups
AFP < 7ng/mL (n = 62) AFP ≥ 7 ng/mL (n = 152) All patients (n = 214)
Sex Male 56 (90%) 114 (75%) 170 (79%)
Female 6 (10%) 38 (25%) 45 (21%)
Age
(n = 207)
Median (IQR) 64.5 (55, 71) 67 (61, 75) 66 (60, 74)
Range 16 – 86 14 – 84 14 – 86
≤ 66 34 (59%) 71 (48%) 105 (51%)
> 66 24 (41%) 78 (52%) 102 (49%)
Child-Pugh A 40 (65%) 100 (66%) 140 (65%)
B 22 (35%) 48 (32%) 70 (33%)
C 0 (0%) 4 (3%) 4 (2%)
NLR ≤ 3.0 40 (65%) 64 (42%) 104 (49%)
> 3.0 22 (35%) 88 (58%) 110 (51%)
Portal vein 
invasion
Yes 13 (21%) 63 (41%) 76 (36%)
No 49 (79%) 89 (59%) 138 (64%)
Aetiology ALD 10 (16%) 20 (13%) 30 (14%)
Hepatitis B 4 (6%) 13 (9%) 17 (8%)
Hepatitis C 7 (11%) 17 (11%) 24 (11%)
NASH 6 (10%) 12 (8%) 18 (8%)
Combination 4 (6%) 8 (5%) 12 (6%)
Unknown/other 31 (50%) 82 (54%) 113 (53%)
Previous 
treatment
TACE 16 (26%) 40 (26%) 56 (26%)
RFA 4 (6%) 4 (3%) 8 (4%)
TACE & RFA 4 (6%) 4 (3%) 8 (4%)
None 38 (61%) 104 (68%) 142 (66%)
Figure 1: Kaplan Meier curve showing survival in patients with NLR ≤ 3 versus NLR > 3.
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that elevated pre-treatment NLR is associated with poorer 
TTP and/or overall survival following sorafenib treatment, 
after adjusting for clinical covariates [17, 18, 28, 29]. 
One major limitation of the existing studies is that all of 
the studies (including ours) have been observational and 
mostly retrospective in nature, and thus the prognostic 
ability of NLR still requires prospective evaluation. 
During the writing of this manuscript, exploratory 
analyses from two prospective studies performed in 
patients with advanced HCC have been published: 
Personeni et al. analysed the prognostic value of NLR in 
patients treated in the ARQ 197–215 study, a randomised 
placebo-controlled study testing the MET inhibitor 
tivantinib in the second line setting for patients with 
advanced HCC [30]. Multivariate analysis revealed that 
baseline NLR was an independent prognostic biomarker in 
this setting; NLR >3 was associated with poorer survival 
(HR1.65; 95% CI 1.05; 2.59; p = 0.03) [30]. Bruix 
et al. conducted a pooled exploratory analysis from the 
2 landmark placebo-controlled phase 3 studies (SHARP 
and Asia-Pacific) in an attempt to identify prognostic 
factors for OS and predictive factors of sorafenib benefit 
[31]. A high NLR (≤ vs >median [3.1]) was a strong 
and independent prognostic factor for overall survival. 
Furthermore, the OS benefit of sorafenib was consistently 
observed in all subgroups but patients with a low NLR 
derived a greater OS benefit from sorafenib treatment 
(HR, 0.59 vs 0.84) [31]. Thus in advanced HCC the 
available literature now robustly supports NLR as an 
independent prognostic factor for survival in this group, 
independent of treatment allocation, in both the first line 
and second line setting.
Another important finding of our study is that 
patients who do not secrete AFP have a significantly 
improved OS. Although low AFP is known to be associated 
with better outcomes in HCC following surgical resection 
and liver transplantation, to our knowledge, this is the 
first time this has been reported for patients undergoing 
sorafenib treatment. 
There is a paucity of research on patients with low 
AFP and HCC and in particular potential prognostic factors 
in this subgroup. In our study, we found no evidence that 
NLR ratio <>3 was associated with survival in the AFP 
non-secretor subgroup, however the numbers of patients 
contributing to this analysis was only small. However, a 
unique finding from our study is the association of low 
Table 2: Overall Survival stratified by NLR
Unadjusted (n = 214) Adjusted1 (n = 214)
NLR Number (%) in higher group HR (95% CI) HR (95% CI) 3
3 110 (51%) 1.45 (1.07, 1.95) 1.32 (0.96, 1.80)
4 62 (29%) 1.22 (0.88, 1.69) 1.27 (0.91, 1.77)
5 42 (20%) 1.47 (1.01, 2.13) 1.39 (0.95, 2.04)
Adjusted for Child-Pugh class, portal vein invasion and ln(AFP).
Figure 2: Kaplan Meier curve showing survival in patients with AFP < 7 and AFP ≥ 7.
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AFP with low NLR, with a much higher proportion of 
patients with low NLR in the AFP non-secretor group 
compared to the AFP secretors. This has not previously 
been reported. Whilst prospective validation of this finding 
is needed, this association may in part explain the better 
prognosis of patients with HCC who do not secrete AFP. 
Recent in vitro studies have demonstrated that tumour-
derived AFP can directly impair natural killer (NK) cell 
activation and viability [32], indirectly impair NK cell 
activity through suppression of dendritic cell function 
[33], and induce aberrant dendritic cell differentiation with 
consequential reduction in the secretion of inflammatory 
cytokines and chemokines and limited T cell activation 
[34, 35]. Thus shifting the balance towards a high NLR in 
the presence of AFP.
There has only been one other study which has 
looked at prognostic biomarkers in the subset of patients 
with low AFP. Carr et al. demonstrated that serum gamma 
glutamyl transpeptidase (GGGT) levels correlated with 
survival in patients with unresectable HCC and low 
AFP [27]. As GGGT is also a readily available test, we 
recommend prospective evaluation of the combination of 
NLR and GGGT in patients with HCC and non-secretion 
of AFP. 
Other prognostic biomarkers associated with 
sorafenib have also been investigated. In the the SHARP 
trial, Llovet et al. analysedplasma biomarkers- Ang2, 
bFGF,VEGF, sVEGFR-2,sVEGFR-3,HGF, s-c-KIT, IGF-
2 and Ras after 12 weeks of treatment with sorafenib [36]. 
This revealed that only Ang2 and VEGF were independent 
predictors of survival but none of the biomarkers were 
predictive of response to treatment [36]. Furthermore 
Masuda et al. recently reported that expression of high 
mobility group box 1 (HMGB1) at 4 weeks was an 
independent predictor of poor overall survival with 
sorafenib treatment (P = 0.001) [37]. However the cost-
effectiveness and availability of these markers in routine 
clinical practise are significant limitations. The advantage 
of NLR and AFP is that they are both inexpensive routine 
blood tests which are frequently used when planning HCC 
treatment.
In summary, we have shown that NLR and non-
secretion of AFP both have potential as prognostic 
biomarkers in patients with advanced HCC treated with 
sorafenib. Further prospective validation of our findings 
is required, in particular the association of low AFP and 
low NLR, but if these findings are validated then these 
may provide clinicians with inexpensive and routinely 
available biomarkers to better help select patients for 
future treatment and clinical trials. 
PATIENTS AND METHODS
All patients with a confirmed diagnosis of HCC, 
either histologically or radiologically as per internationally 
accepted American Association for Study of Liver 
Diseases (AASLD) criteria, who commenced treatment 
with sorafenib at our centre between April 2009 and 
March 2014 were included in this analysis. 
Electronic patient records were reviewed and 
variables including demographics, haematological and 
biochemical laboratory results, radiological data and 
survival outcomes were collected. Survival analysis was 
performed using the Kaplan-Meier method, Cox regression 
and log-rank tests. All analyses were performed in Stata 14.
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